Colleen Kusy
Stock Analyst at Baird
(0)
# 4727
Out of 5,368 analysts
56
Total ratings
29.73%
Success rate
-17.07%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AGEN Agenus | Maintains: Neutral | 4 6 | 4.69 | 27.93% | 4 | Jun 4, 2025 | |
APLS Apellis Pharmaceutic... | Maintains: Outperform | 55 47 | 18.84 | 149.47% | 11 | May 8, 2025 | |
OCS Oculis Holding | Maintains: Outperform | 37 41 | 19.35 | 111.89% | 4 | Mar 13, 2025 | |
CHRS Coherus BioSciences | Maintains: Outperform | 4 6 | 0.76 | 689.47% | 5 | Dec 5, 2024 | |
ELVN Enliven Therapeutics | Maintains: Outperform | 32 40 | 21.91 | 82.57% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 65 | 17.31 | 275.51% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 3 | n/a | n/a | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 17 | 8.72 | 94.95% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 27 25 | 9.63 | 159.61% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 105 | 78.3 | 34.1% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 40 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 15 | n/a | n/a | 1 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 255 210 | 4.4 | 4672.73% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 34 | 2.25 | 1411.11% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 230 | 1.72 | 13272.09% | 1 | Nov 2, 2021 |